Study #2024-0264
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 capsules in patients with advanced solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
BGC515
Description
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-424-0935
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.